Literature DB >> 18783315

Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.

Karen E Mark1, Anna Wald, Amalia S Magaret, Stacy Selke, Laura Olin, Meei-Li Huang, Lawrence Corey.   

Abstract

BACKGROUND: Herpes simplex virus (HSV) remains latent in nerve root ganglia of infected persons and is thought to reactivate several times yearly. Recent in situ data show the localization of HSV-specific CD8(+) T cells at the dermal epidermal junction next to peripheral sensory nerve endings, suggesting that viral reactivation may occur more frequently than previously appreciated.
METHODS: Twenty-five HSV-2-seropositive and 18 HSV-1-seropositive healthy adults collected anogenital and oral swabs, respectively, 4 times per day for 60 days. Swabs were assayed for HSV, using a quantitative polymerase chain reaction assay.
RESULTS: Twenty-four percent of anogenital reactivations and 21% of oral reactivations lasted < or =6 h, and 49% of anogenital reactivations and 39% of oral reactivations lasted < or =12 h. Lesions were reported in only 3 (7%) of 44 anogenital reactivations and 1 (8%) of 13 oral reactivations lasting < or =12 h. The median HSV DNA levels at initial and last detection were 10(3.5) and 10(3.3) copies/mL, respectively, during anogenital reactivation and 10(3.7) and 10(3.0) copies/mL, respectively, during oral reactivation.
CONCLUSIONS: This high frequency of short subclinical HSV reactivation in immunocompetent hosts strongly suggests that the peripheral mucosal immune system plays a critical role in clearing HSV reactivations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783315      PMCID: PMC2667115          DOI: 10.1086/591913

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Evolution of recurrent herpes simplex lesions. An immunohistologic study.

Authors:  A L Cunningham; R R Turner; A C Miller; M F Para; T C Merigan
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

2.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

3.  Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture.

Authors:  Anna Wald; Meei-Li Huang; David Carrell; Stacy Selke; Lawrence Corey
Journal:  J Infect Dis       Date:  2003-10-31       Impact factor: 5.226

4.  Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.

Authors:  Catherine M Crespi; William G Cumberland; Anna Wald; Lawrence Corey; Sally Blower
Journal:  Sex Transm Infect       Date:  2007-05-02       Impact factor: 3.519

5.  Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.

Authors:  Timothy Schacker; Judith Zeh; Huilin Hu; Mary Shaughnessy; Lawrence Corey
Journal:  J Infect Dis       Date:  2002-11-22       Impact factor: 5.226

6.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia.

Authors:  Kamal M Khanna; Robert H Bonneau; Paul R Kinchington; Robert L Hendricks
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

7.  Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant.

Authors:  Zane A Brown; Anna Wald; R Ashley Morrow; Stacy Selke; Judith Zeh; Lawrence Corey
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

8.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Authors:  Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

9.  Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection.

Authors:  Pierre-Yves Bochud; Amalia S Magaret; David M Koelle; Alan Aderem; Anna Wald
Journal:  J Infect Dis       Date:  2007-06-29       Impact factor: 5.226

Review 10.  The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.

Authors:  Lawrence Corey; Anna Wald; Connie L Celum; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

View more
  122 in total

1.  Neonatal Herpes Infection Associated With Direct Orogenital Suction During Ritual Jewish Circumcision.

Authors:  Rebecca Pellett Madan; Betsy C Herold; Adam J Ratner; Lisa Saiman; Anne A Gershon; Lawrence R Stanberry
Journal:  J Pediatric Infect Dis Soc       Date:  2015-04-24       Impact factor: 3.164

2.  Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.

Authors:  Warren Phipps; Misty Saracino; Amalia Magaret; Stacy Selke; Mike Remington; Meei-Li Huang; Terri Warren; Corey Casper; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2010-12-09       Impact factor: 5.226

3.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

4.  HSV-1 as well as HSV-2 is frequent in oral mucosal lesions of children on chemotherapy.

Authors:  Ritu Aggarwal; Deepak Bansal; Jasmine Naru; Manila Salaria; Anita Rana; Ranjana W Minz; Amita Trehan; R K Marwaha
Journal:  Support Care Cancer       Date:  2014-02-14       Impact factor: 3.603

5.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

6.  Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Authors:  Christine Johnston; Jia Zhu; Lichen Jing; Kerry J Laing; Christopher M McClurkan; Alexis Klock; Kurt Diem; Lei Jin; Jeffrey Stanaway; Elizabeth Tronstein; William W Kwok; Meei-Li Huang; Stacy Selke; Youyi Fong; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 7.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

8.  Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception.

Authors:  Gail F Shust; Sylvia Cho; Mimi Kim; Rebecca P Madan; Esmeralda M Guzman; Margaret Pollack; Julia Epstein; Hillel W Cohen; Marla J Keller; Betsy C Herold
Journal:  Am J Reprod Immunol       Date:  2009-12-15       Impact factor: 3.886

9.  Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.

Authors:  Sunitha Tata; Christine Johnston; Meei-Li Huang; Stacy Selke; Amalia Magaret; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

10.  A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.

Authors:  Manish Kumar; James M Hill; Christian Clement; Emily D Varnell; Hilary W Thompson; Herbert E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.